Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age12+
SponsorRiphah International University

About this trial

The goal of this clinical trial is to learn if injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts works to clear them in people aged 12 and older with common, plantar, flat, or periungual (around the nail) warts. The main questions it aims to answer are:

1. Does intralesional acyclovir or vitamin D3 lead to complete clearance of warts by week 8? 2. Which treatment clears warts more effectively? 3. What side effects do participants have with each treatment?

Researchers will compare acyclovir injections (Group A) to vitamin D3 injections (Group B), with 20 participants in each group, to see which treatment works better at clearing warts.

Participants will:

1. Receive an injection directly into the wart every 2 weeks for up to 4 sessions 2. Have photographs taken of their warts before treatment and at each visit 3. Visit the clinic for checkups where the size and number of warts will be measured 4. Be followed for up to 3 months to check for wart recurrence and side effects

Eligibility criteria

Qualifiers

Patients aged 12 years and above with clinically diagnosed cutaneous warts

Common, plantar, flat, or periungual warts

Both treatment-naïve patients and those with recalcitrant warts

Disqualifiers

Pregnant or lactating women

Immunocompromised patients

Individuals with history of hypersensitivity to vitamin D3 or acyclovir

Individuals receiving systemic immunosuppressive or antiviral therapy

Trial design

Treatments tested in this trial

  • Intralesional Acyclovir
  • Intralesional Vitamin D3

Treatment groups

40 Participants
are divided into 2 treatment groups